Loading…
Loading…
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
Brookfield Real Assets Income Fund Inc. (NYSE: RA - Get Free Report) declared a monthly dividend on Friday, September 25th. Investors of record on Friday, October 9th will be given a dividend of $0.1180 per share on Friday, October 23rd. This represents a $1.42 dividend on an annualized basis and a dividend yield of 12.3%. The
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Brookfield Real Assets Income Fund Inc. (NYSE: RA). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Brookfield Real Assets Income Fund stock on August 31st. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account. Representative Kevin
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund's monthly distributions for October, November and December 2026.
AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
Brookfield Real Assets Income Fund Inc. (NYSE: RA - Get Free Report) was the target of a large decrease in short interest in August. As of August 14th, there was short interest totaling 56,549 shares, a decrease of 36.8% from the July 30th total of 89,421 shares. Based on an average daily trading volume, of 144,278